Treatment of refractory and recurrent ovarian cancer

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

Patients with recurrent ovarian cancer can be divided into two groups: those who have recurrence more than 6 months after primary therapy with paclitaxel/platinum (ie, platinum-sensitive) and those with tumor progression or recurrence within 6 months of primary therapy (ie, platinum-resistant). In patients with platinum-sensitive tumors and good performance status, re- treatment with paclitaxel/platinum combination therapy is usually the most appropriate choice. For patients with minimum residual disease, the greatest promise for long-term disease-free survival is associated with intensive intraperitoneal therapy with combinations of cisplatin and intravenous/intraperitoneal paclitaxel. Alternatively, patients with platinum-sensitive disease can receive intravenous carboplatin or paclitaxel. Patients with platinum-resistant ovarian cancer can benefit from single- agent therapy with altretamine, topotecan, oral etoposide, ifosfamide, liposomal doxorubicin, or other standard or investigational regimens. (Of these drugs, only altretamine and topotecan are approved by the US Food and Drug Administration for persistent or recurrent ovarian cancer). Since the response rates achieved with these drugs are similar, patient convenience, side effects, and cost may play a significant: role in drug selection.

Original languageEnglish (US)
Pages (from-to)8-14
Number of pages7
JournalSeminars in Oncology
Volume26
Issue number1 SUPPL.
StatePublished - 1999

Fingerprint

Platinum
Ovarian Neoplasms
Paclitaxel
Altretamine
Topotecan
Therapeutics
Pharmaceutical Preparations
Recurrence
Ifosfamide
Carboplatin
Etoposide
United States Food and Drug Administration
Cisplatin
Disease-Free Survival
Neoplasms
Costs and Cost Analysis

ASJC Scopus subject areas

  • Oncology

Cite this

Treatment of refractory and recurrent ovarian cancer. / Alberts, David S.

In: Seminars in Oncology, Vol. 26, No. 1 SUPPL., 1999, p. 8-14.

Research output: Contribution to journalArticle

@article{ccbb7ae3614e403bb4349ab51d4ae51a,
title = "Treatment of refractory and recurrent ovarian cancer",
abstract = "Patients with recurrent ovarian cancer can be divided into two groups: those who have recurrence more than 6 months after primary therapy with paclitaxel/platinum (ie, platinum-sensitive) and those with tumor progression or recurrence within 6 months of primary therapy (ie, platinum-resistant). In patients with platinum-sensitive tumors and good performance status, re- treatment with paclitaxel/platinum combination therapy is usually the most appropriate choice. For patients with minimum residual disease, the greatest promise for long-term disease-free survival is associated with intensive intraperitoneal therapy with combinations of cisplatin and intravenous/intraperitoneal paclitaxel. Alternatively, patients with platinum-sensitive disease can receive intravenous carboplatin or paclitaxel. Patients with platinum-resistant ovarian cancer can benefit from single- agent therapy with altretamine, topotecan, oral etoposide, ifosfamide, liposomal doxorubicin, or other standard or investigational regimens. (Of these drugs, only altretamine and topotecan are approved by the US Food and Drug Administration for persistent or recurrent ovarian cancer). Since the response rates achieved with these drugs are similar, patient convenience, side effects, and cost may play a significant: role in drug selection.",
author = "Alberts, {David S}",
year = "1999",
language = "English (US)",
volume = "26",
pages = "8--14",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "1 SUPPL.",

}

TY - JOUR

T1 - Treatment of refractory and recurrent ovarian cancer

AU - Alberts, David S

PY - 1999

Y1 - 1999

N2 - Patients with recurrent ovarian cancer can be divided into two groups: those who have recurrence more than 6 months after primary therapy with paclitaxel/platinum (ie, platinum-sensitive) and those with tumor progression or recurrence within 6 months of primary therapy (ie, platinum-resistant). In patients with platinum-sensitive tumors and good performance status, re- treatment with paclitaxel/platinum combination therapy is usually the most appropriate choice. For patients with minimum residual disease, the greatest promise for long-term disease-free survival is associated with intensive intraperitoneal therapy with combinations of cisplatin and intravenous/intraperitoneal paclitaxel. Alternatively, patients with platinum-sensitive disease can receive intravenous carboplatin or paclitaxel. Patients with platinum-resistant ovarian cancer can benefit from single- agent therapy with altretamine, topotecan, oral etoposide, ifosfamide, liposomal doxorubicin, or other standard or investigational regimens. (Of these drugs, only altretamine and topotecan are approved by the US Food and Drug Administration for persistent or recurrent ovarian cancer). Since the response rates achieved with these drugs are similar, patient convenience, side effects, and cost may play a significant: role in drug selection.

AB - Patients with recurrent ovarian cancer can be divided into two groups: those who have recurrence more than 6 months after primary therapy with paclitaxel/platinum (ie, platinum-sensitive) and those with tumor progression or recurrence within 6 months of primary therapy (ie, platinum-resistant). In patients with platinum-sensitive tumors and good performance status, re- treatment with paclitaxel/platinum combination therapy is usually the most appropriate choice. For patients with minimum residual disease, the greatest promise for long-term disease-free survival is associated with intensive intraperitoneal therapy with combinations of cisplatin and intravenous/intraperitoneal paclitaxel. Alternatively, patients with platinum-sensitive disease can receive intravenous carboplatin or paclitaxel. Patients with platinum-resistant ovarian cancer can benefit from single- agent therapy with altretamine, topotecan, oral etoposide, ifosfamide, liposomal doxorubicin, or other standard or investigational regimens. (Of these drugs, only altretamine and topotecan are approved by the US Food and Drug Administration for persistent or recurrent ovarian cancer). Since the response rates achieved with these drugs are similar, patient convenience, side effects, and cost may play a significant: role in drug selection.

UR - http://www.scopus.com/inward/record.url?scp=0032964713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032964713&partnerID=8YFLogxK

M3 - Article

C2 - 10071969

AN - SCOPUS:0032964713

VL - 26

SP - 8

EP - 14

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 1 SUPPL.

ER -